Choroideremia associated with choroidal neovascularization treated with intravitreal bevacizumab

Neal V. Palejwala, Andreas K. Lauer, Richard G. Weleber

Research output: Contribution to journalArticlepeer-review

18 Scopus citations


Purpose: To report a rare case of central vision loss in a patient with choroideremia.

Patients and methods: A retrospective, interventional case report.

Results: A 13-year-old male with history of choroideremia presented with subacute loss of central acuity in his left eye. Examination and diagnostic testing revealed subretinal fibrosis secondary to a choroidal neovascular membrane (CNVM). A trial of anti-vascular endothelial growth factor (VEGF) therapy with the injection of intravitreal bevacizumab was attempted. Mild improvements in acuity and anatomy were noted.

Conclusion: Choroideremia is a rare hereditary choroidal dystrophy that predominantly affects males in the first and second decades of life. Visual acuity is usually spared until later in life. CNVM is a rare manifestation of choroideremia with only a handful of case reports presented in the literature. This case is unique in that it is the first reported case that received treatment with intravitreal anti-VEGF therapy.

Original languageEnglish (US)
Pages (from-to)1675-1679
Number of pages5
JournalClinical Ophthalmology
StatePublished - Sep 1 2014


  • Anti-VEGF therapy
  • Chorioretinal degeneration
  • Choroidal neovascular membrane
  • Choroideremia
  • Hereditary choroidal dystrophy
  • Intravitreal bevacizumab injection

ASJC Scopus subject areas

  • Ophthalmology


Dive into the research topics of 'Choroideremia associated with choroidal neovascularization treated with intravitreal bevacizumab'. Together they form a unique fingerprint.

Cite this